Clinical Trials
2.6k
Trial Phases
6 Phases
Drug Approvals
92
Clinical Trials
Distribution across different clinical trial phases (2081 trials with phase data)• Click on a phase to view related trials
A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it Helps
- Conditions
- Solid TumoursMelanoma
- Interventions
- Drug: BI 3810944
- First Posted Date
- 2025-11-04
- Last Posted Date
- 2025-11-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 75
- Registration Number
- NCT07224425
- Locations
- 🇺🇸
University of Louisville, Louisville, Kentucky, United States
🇺🇸Centennial Medical Center, Nashville, Tennessee, United States
🇧🇪Cliniques Universitaires Saint-Luc, Brussels, Belgium
A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body
- First Posted Date
- 2025-10-28
- Last Posted Date
- 2025-10-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 100
- Registration Number
- NCT07221591
- Locations
- 🇩🇪
CRS Clinical Research Services Berlin GmbH, Berlin, Germany
🇩🇪CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
- Conditions
- Focal Segmental Glomerulosclerosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-10-23
- Last Posted Date
- 2025-10-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 286
- Registration Number
- NCT07220083
- Locations
- 🇺🇸
Nephrology Consultants, LLC, Huntsville, Alabama, United States
🇺🇸Amicis Research Center - Balboa, Granada Hills, California, United States
🇺🇸Academic Medical Research Institute - Glendale, Los Angeles, California, United States
A Study in Healthy People to Test Whether BI 3000202 Affects How 2 Other Medicines (Rosuvastatin and Digoxin) Are Taken up in the Body
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2025-10-10
- Last Posted Date
- 2025-10-10
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 14
- Registration Number
- NCT07215260
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
A Study in Healthy People to Test How Itraconazole Influences the Amount of BI 3031185 in the Blood
- First Posted Date
- 2025-10-08
- Last Posted Date
- 2025-10-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 14
- Registration Number
- NCT07211425
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
- Prev
- 1
- 2
- 3
- 4
- 5
- 450
- Next
News
HRSA Approves Eight Drug Companies for 340B Rebate Model Pilot Program Starting January 2025
The Health Resources and Services Administration has approved eight pharmaceutical companies to participate in the 340B Rebate Model Pilot Program, which will begin on January 1, 2025.
Boehringer Ingelheim Licenses First-in-Class Small Molecule from Kyowa Kirin for Autoimmune Disease Treatment
Boehringer Ingelheim has acquired exclusive worldwide rights to a pre-clinical small molecule program from Kyowa Kirin targeting autoimmune diseases.
Boehringer Ingelheim Acquires First-in-Class Oncology Asset from Accent Therapeutics Targeting High ISG Expression Tumors
Boehringer Ingelheim has acquired a potentially first-in-class preclinical small molecule program from Accent Therapeutics targeting tumors with high interferon-stimulated gene (ISG) expression.
Qurient and Synaffix Partner to Develop First-in-Class CDK7 Dual-Payload ADC for Refractory Cancers
Qurient has signed a licensing agreement with Synaffix to develop a dual-payload ADC combining Qurient's CDK7 inhibitor mocaciclib with Synaffix's exatecan-based technology.
TegMine Therapeutics Partners with Boehringer Ingelheim to Develop Next-Generation ADCs Using Novel 2-Factor Antibody System
TegMine Therapeutics has entered a strategic research collaboration with Boehringer Ingelheim to develop safer, more selective antibody-drug conjugates using TegMine's proprietary 2-Factor Antibody System.
Roche Acquires 89bio for $3.5 Billion to Strengthen MASH Treatment Pipeline
Roche announced a definitive merger agreement to acquire 89bio for $14.50 per share in cash plus contingent value rights, totaling up to $3.5 billion.
UPC Court of Appeal Grants First Pharmaceutical Preliminary Injunction, Setting New Standard for Generic Drug Market Entry
The Unified Patent Court's Court of Appeal granted its first preliminary injunction in the pharmaceutical sector, blocking Zentiva from launching generic versions of Boehringer Ingelheim's Ofev across 17 European territories.
FDA Accepts First Non-Invasive Surrogate Endpoint for MASH Clinical Trials
The FDA has accepted Echosens' Letter of Intent to qualify liver stiffness measurement by FibroScan® as the first non-invasive surrogate endpoint for MASH clinical trials.
DAPA ACT HF-TIMI 68 Trial Shows Promise for In-Hospital SGLT2 Inhibitor Initiation Despite Missing Primary Endpoint
The DAPA ACT HF-TIMI 68 trial failed to show significant improvement in cardiovascular death or worsening heart failure when starting dapagliflozin during acute heart failure hospitalization, with 10.9% of treated patients versus 12.7% of placebo patients experiencing events at 60 days.
Controlled Release Drug Delivery Market Expands with Major Pharma Investment in Precision Medicine Technologies
Major pharmaceutical companies including AbbVie, AstraZeneca, and Merck are actively developing controlled drug release systems to enhance treatment of chronic diseases, cancer, and neurological disorders.